Rosetta Genomics

ROSGQ · OTC

Price unavailable right now.

No price history for this range.

About ROSGQ

Rosetta Genomics Ltd. engages in the provision of therapeutic, diagnostic product development, and medical research services. The firm is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY, and RosettaGX Reveal. The firm's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The firm focuses on developing a diagnostic assay, RosettaGX Reveal V2. The company is also focusing on developing Bladder cancer risk stratification.

Employees: 86
Headquarters: REHOVOT
Listed: Feb 27, 2007
Sector: Health Care
Industry: Biotechnology
Website: rosettagenomics.com

Leadership

Rosetta Genomics executives
Name	Title	Age
Brian Markison	—	65
Ron Kalfus	—	41
Sigal Russo-Gueta	—	38
Dganit Bar	—	47
Eti Meiri	—	47
Roy Davis	—	69
Gerald Dogon	—	76
Joshua Rosensweig	—	—
David Sidransky	—	65
Tali Yaron-Eldar	—	55

Similar companies

Companies in the same industry as Rosetta Genomics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.